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Common pancreatic ductal adenocarcinoma (PDC) is character-
ized by a relatively unique molecular fingerprint constituted by
frequent alterations of the K-ras (Almoguera et al, 1988; Lemoine
et al, 1992;), p53 (Barton et al, 1991; Kalthoff et al, 1993; Scarpa
et al, 1993a), p16INK4a (Caldas et al, 1994) and DPC4/Smad4 genes
(Hahn et al, 1996). Numerous studies on K-ras and  p53 have
confirmed that they are mutated at high frequency in primary PDC
(K-ras reviewed in Hruban et al, 1993 and Scarpa et al, 1994a; for
p53 see: Pellegata et al, 1994; Redston et al, 1994). Less informa-
tion is available regarding alterations of p16 and DPC4 in primary
PDC and the only two available reports suggested that alterations
in these two genes occur less frequently in primary PDC than in
derived cell lines (Huang et al, 1996; Bartsch et al, 1999a). Studies
on xenografts and cell lines have shown that homozygous dele-
tions may account for up to half of all instances of inactivation of
these genes (Caldas et al, 1994; Hahn et al, 1996; Naumann et al,
1996; Villanueva et al, 1998) although this phenomenon is diffi-
cult to demonstrate in primary PDC due to the high admixture of
nonneoplastic cells in these tissues. In addition, the p16 gene may
also be silenced by promoter methylation (Schutte et al, 1997), an
epigenetic event not yet examined in a series of primary PDC. 
Very little is known about the molecular abnormalities
in neoplasms other than ductal arising from the exocrine pan-
creas, including intraductal papillary-mucinous tumours (IPMT),
solid-pseudopapillary tumours (SPT), the cystic group of malig-
nancies, the extremely rare acinar cell carcinomas (PAC), and
cancers arising from the ampulla (papilla) of Vater (AVC)
(Klöppel et al, 1996; Solcia et al, 1997). 
Based on the mutational analysis of the K-ras and p53 genes in
35 PDC, 6 pancreatic exocrine nonductal and 12 pancreatic
endocrine tumours (PET), an earlier study concluded that the
molecular pathogenesis of exocrine nonductal and endocrine
tumours involves pathways different from those involved in PDC
(Pellegata et al, 1994). However, two recent reports of highly
frequent alterations of the p16 and DPC4 genes in PET suggested
that common molecular pathways are involved in the tumori-
genesis of exocrine and endocrine epithelia (Muscarella et al,
1998; Bartsch et al, 1999b). 
To address these issues specifically, we have analysed 112
primary pancreatic tumours of different types, including 34 PDC,
37 exocrine nonductal and 41 PET, for molecular alterations in
p16 and DPC4 genes. The inactivation of the DPC4 gene by addi-
tional mechanisms such as homozygous deletion was studied
using immunohistochemistry, which has been shown to correlate
with inactivation of the gene (Wilentz et al, 2000). All tumours
were also presently or previously analysed for K-ras and  p53
mutations and allelic loss at chromosomal arms 9p, 17p and 18q at
sites linked to p16, p53 and DPC4 genes. This study represents the
largest report to date on the mutational status of different pancre-
atic tumour types for the 4 genes most commonly altered in
pancreatic ductal cancers and provides evidence that only ductal
and ampulla of Vater cancers share common molecular anomalies,
while the less common tumour entities have a distinct molecular
pathogenesis. 
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All the studies performed were approved by the Ethics Committee
of Verona University. 
Primary tumours 
The 112 frozen pancreatic tumours consisted of 34 PDC, 37
exocrine nonductal and 41 PET. The nonductal exocrine tumours
were composed of 10 1PMT, 6 PAC, 5 SPT and 16 AVC. The PETs
included 30 nonfunctional and 11 functional tumours. A neoplastic
cellularity of at least 60% for PDC and ranging from 70% to virtu-
ally 100% for all other tumour types was obtained in all cases by
either cryostat enrichment or microdissection of the frozen tumour
samples, as described (Achille et al, 1996a; Sorio et al, 1999). 
Among the 34 PDC, 18 cases had been previously analysed for
mutations in the K-ras and p53 genes; in particular, PDC3-PDC6
and PDC9-PDC11 were described in Achille et al (Achille et al,
1996a) and PDC19-PDC29 correspond to previously reported
cases 1, 4, 5, 7, 8, 10, 11, 12, 14, 15 and 21 (Scarpa et al, 1993a).
The remaining 16 cases have not been previously reported. 
The 10 IPMT were characterized by diffuse or segmental
dilatation of the main and/or branch pancreatic ducts with intra-
ductal growth pattern sometimes forming intraluminal masses,
which presented a wide spectrum of modifications ranging from
low-to high-grade dysplasia and from carcinoma in situ to invas-
ive cancer (Klöppel et al, 1996; Solcia et al, 1997). In particular, 3
cases had only the intraductal component and were considered of
borderline malignancy, according to established criteria (Klöppel
et al, 1996; Solcia et al, 1997), 7 cases also had an invasive
component which was represented by muconodular carcinoma in
6 and ductal-like cancer in one. Cases IPMT1-IPMT4 correspond
to cases 4, 5, 2 and 3, respectively, of a previous report in which
they had been analysed for K-ras and p53 mutations (Sessa et al,
1994). 
The 5 SPT were from prepubertal girls or young women, and
characteristically showed progesterone receptor immunostaining
(Zamboni et al, 1993). These cases have not been previously
reported. 
The 6 PAC were diagnosed by histopathological criteria and cell
marker analysis. The latter confirmed the acinar nature of the
neoplastic cells, which expressed lipase in all cases, amylase in 2
cases, trypsin in 5 and chymotrypsin in 4 cases (Klimstra et al,
1992; Hoorens et al, 1993; Solcia et al, 1997). These cases have
not been previously reported. 
The 16 AVC were selected by applying strict topographical
criteria obtained at gross and histological examinations. Only
small lesions with unequivocal ampullary origin, topographically
centred in the region of the papilla of Vater were included in the
study (Achille et al, 1996b, 1998; Scarpa et al, 1993b, 1994b).
AVC showing microsatellite instability of the type seen in replica-
tion error phenotype (RER+) cancers were excluded from the
study (Achille et al, 1997). All cases except AVC16 have been
previously described and analysed for mutations in the K-ras and
p53 genes and for 17p and 18q LOH (Scarpa et al, 2000). 
The series of 41 PET was composed of 30 nonfunctional and 11
functional tumours, including 9 insulinomas, 1 gastrinoma and 1
VIPoma. 23 tumours were benign and 18 malignant, in accordance
with the respective absence or presence of invasion of the neigh-
bouring organs and/or nodal/distant metastases, as evaluated by
imaging techniques, surgical and pathological examinations. All
tumours were characterized using a panel of monoclonal anti-
bodies recognizing pan-endocrine markers (chromogranin A,
synaptophysin and non-specific enolase) and gastrointestinal
hormones (insulin, glucagon, somatostatin, pancreatic polypep-
tide, gastrin, serotonin, and vasoactive intestinal peptide). Only
those tumours giving rise to an endocrine syndrome were consid-
ered as functional. PETs were considered nonfunctional if clinical
symptoms were absent, regardless of the immunostaining results.
Among the 30 nonfunctional tumours, 24 showed no immunore-
activity for the tested hormones, while 4 tested positive for
glucagon and 2 for somatostatin. Mutations in the K-ras and p53
genes for tumours NF1–NF10 and F1–F6 have been previously
reported (Beghelli et al, 1998). All other cases have not been
previously reported. 
Loss of heterozygosity analysis 
Most cases were analysed for allelic loss with high-molecular
weight DNA, although some analyses were performed with DNA
extracted from paraffin-embedded tissues prepared as described
(Scarpa et al, 2000). Two microsatellites each were used for
chromosomal arms 9p, 17p, and 18q. All cases were analysed for
allelic loss using the microsatellite markers D9S171,  D9S161,
D17S799, and D18S474. For high molecular weight DNA, the
markers D17S938 and  D18S64 were also used. For paraffin-
embedded samples, the markers D17S1857 and D18S1102 were
used as alternatives. These markers are part of the AB1 Prism,
Linkage Mapping Set, ver. 1 and 2 (Perkin Elmer). PCR products
were pooled and electrophoresed on an AB1 Prism 377 instru-
ment. Electropherograms were analysed for microsatellite alter-
ations using GeneScan v. 3.1 and Genotyper v. 2.5 software
(Perkin Elmer). Only microsatellites showing two distinct alleles
in normal DNA were considered as informative. LOH was scored
when there was loss of intensity of one allele in the tumour
sample with respect to the matched allele from normal tissue and
the relative intensity of the 2 alleles in the tumour DNA differed
from the relative intensity in the non-neoplastic tissue DNA by a
factor of at least two. All the analyses were verified by visual
examination. Microsatellites showing differently sized alleles
compared with their respective normal sample were scored as
unstable. LOH on each chromosomal arm was scored in cases
showing allelic loss in at least one informative marker for that
arm. 
Mutational analysis of K-ras, p16, and p53 and DPC4
All samples were analysed for mutations in exon 1 of the K-ras
gene, exons 1 and 2 of p16, exons 5–9 of p53, and exons 8–11 of
DPC4 by single-strand conformation polymorphism (SSCP) and
direct sequencing of PCR amplified DNA fragments. PCR was
performed in a volume of 10 µl using 40 ng DNA with 35 cycles.
Primers for amplification of the p53 (Scarpa et al, 1993a), p16
(Zhang et al, 1994), K-ras (Scarpa et al, 1994b) and DPC4 genes
(Hahn et al, 1998) were as described. For SSCP analysis, 0.1 µl
[a-32P]-dCTP (3000 Ci mmol-1) was added to the amplifications.
Samples were run on 5% polyacrylamide gels containing 0.125%
bis-acrylamide with and without 5% glycerol at 30 W. Bands
exhibiting aberrant migration were cut from the gel, re-amplified,
and sequenced on an AB1 Prism 377 instrument. The DNA from 6
xenografted control samples were a kind gift of Dr S Hahn,
University of Bochum, Germany (Hahn et al, 1996). 
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As we found a relatively low number of DPC4 mutations using the
PCR-amplified fragments described (Hahn et al, 1998), a second
round of PCR-SSCP for exons 8–11 was carried out using smaller
amplified fragments to verify the sensitivity of SSCP. Exons 8–11
were each divided into two fragments, each less than 180 bp.
The primers used and the size of the amplified fragments were
as follows. Exon 8A (167 bp): DPC4Ex8B, AAGCCT-
TATATCTTTCTCATGG, DPC4AS18, GAAGGGTCCACG-
TATCCAT; Exon 8B (157 bp): DPC4S18, GTTCCTTC-
AAGCTGCCCTAT, DPC4AS8, CAATTTTTTAAAGTAACTATC
TGA; Exon 9A (175 bp): DPC4Ex9B, CTATACAATCTGAAG-
TAAAATT, DPC4AS19, AGTAGTAACTCTGTACAAAG; Exon
9B, (173 bp): DPC4S19, TTGGGTCAGGTGCCTTAGT,
DPC4Ex9, TTTTGACAACAAATAGAGCTTTAAGTC; Exon
10A (145 bp): DPC4Ex10, GAATTTTCTTTATGAACTCATAG,
DPC4IAS10, GGATGTTTCCTGCCACGGC; Exon 10B (155
bp): DPC41S10, CACAAGCTGCAGCAGCTGCC, DPC4-
Ex10B, ATCAACTGAGTAAATCAAGATAA; Exon 11A (179
bp): DPC4S11B, TCACCCTGTCCCTCTGATG, DPC41AS11,
AGTGAATTTCAATCCAGCAA; Exon 11B (176 bp): DPC-
41S11, TTACCCAAGACAGAGCATCA, DPC4Ex11, TATTTT-
GTAGTCCACCATC. 
Methylation analysis of p16
Methylation-specific PCR for the 5’ CpG island of the p16 gene
was carried out as described (Herman et al, 1996). DNA from the
cell-line PaTul (kindly provided by Dr M von Bulow, University
of Mainz, Germany) was used as a positive control and for evalua-
tion of the sensitivity of methylation-specific PCR under the
conditions used. 
Immunohistochemistry for p16 and DPC4 
Immunohistochemistry for p16 was performed using 3 different
mouse monoclonal antibodies (p16 Ab G175-405 from BD
PharMingen, San Diego, USA; Neomarker p16 Ab-4 (clone
16P04) from Lab Vision Corporation, Fremont, USA; Santa Cruz
p16 (F-12) from Autogen Bioclear, Calne, UK) at dilutions from
1:10 to 1:100 using different antigen retrieval and signal
enhancing procedures. Immunohistochemistry for DPC4/Smad4
was performed using a mouse monoclonal antibody (Santa Cruz
Smad4 (B-8) from Autogen Bioclear, Calne, UK) at a dilution of
1:100 following antigen retrieval by microwaving for 3 times 10
min each in 10 mM citrate buffer, pH 6. 
The immunolabelling for DPC-4 was scored as positive or
negative. Tumours scored as positive showed diffuse cytoplasmic
staining of the tumour epithelium and had scattered positive
nuclei. Tumours scored as negative showed no detectable cyto-
plasmic or nuclear DPC-4 protein. Normal pancreatic structures in
the same sections served as positive controls. Cases with focal loss
of expression were scored as focal positive. 
RESULTS 
All 112 primary tumours were analysed for mutations in the DPC4
and  p16 genes. Representative SSCP analyses are shown in
Figures 1 and 2. The p16 gene was also examined for methylation
of its 5' CpG island by methylation-specific PCR, a representative
example of which is shown in Figure 3. Under the conditions used,
p16 methylated sequences could be detected when they repres-
ented 2% or greater of the total input DNA (data not shown). All
112 tumours were presently or previously analysed for mutations
in K-ras and p53 genes. The 53 previously reported cases included
18 PDC, 4 IPMT, 15 AVC and 16 PET (details in Materials and
Methods). All tumours were also examined for allelic loss on chro-
mosomal arms 9p, 17p and 18q at sites linked to p16, p53 and
DPC4, respectively. Representative examples of this analysis are
shown in Figure 4. 
The status of p16 and  DPC4 genes was also analysed by
immunohistochemistry. However, none of the 3 anti-p16 anti-
bodies consistently stained any structure or cell in normal pancreas
with the exception of the Ab-4 from Neomarkers, which only
showed positivity in variable portions of the islets of Langerhans
(data not shown) confirming previous observations (Nielsen et al,
1999). Thus, the analysis of p16 status by immunohistochemistry
was not feasible, as any observed negativity in neoplastic cells
could not be interpreted in the absence of reliable positive controls
(see also: Wilentz et al, 1998; Geradts et al, 2000). On the other
hand, the anti-DPC4 antibodies efficiently immunostained all
normal pancreatic acinar, ductal and islet cells, which showed
strong to intermediate cytoplasmic reactivity with occasional
nuclear labelling. Representative examples of immunohistochem-
istry with anti-DPC4 antibodies are shown in Figure 5. 
Ductal carcinomas 
The results of the analysis of 34 cases are summarized in Table 1.
Mutations in K-ras and p53 were found in 82% and 53% of cases,
respectively. Either methylation or mutation of the p16 gene was
observed in 38% of cases. All mutations were somatic in nature
with the exception of the p16 gene alteration in case PDC16,
which was germline in origin (Moore et al, 2000b). Mutations in
DPC4 were found in 9% of cases. Two recently identified poly-
morphisms in the DPC4 gene were also found (Table 1) (Moore et
al, 2000a). To rule out the possibility that we were not able to
detect sequence variants with the PCR fragments used for SSCP,
each exon was subsequently analysed using two fragments less
than 180 bp in length and direct DNA sequencing was performed.
No additional mutations were found. As a further control, we were
able to detect all DPC4 mutations by our PCR-SSCP conditions in
6 xenografted PDC (data not shown) kindly furnished by Dr S
Hahn (Hahn et al, 1996). Allelic loss on chromosomal arms 9p,
17p, and 18q was found in 67%, 77%, and 65% of cases, respect-
ively (Table 1). Immunohistochemical staining for DPC4 revealed
that 14 cases (47%) were negative for the protein, including one
case showing focal positivity. All the remaining 16 cases tested
had diffusely positive labelling (Fig. 5). 
Intraductal-papillary-mucinous, solid-pseudopapillary
and acinar tumours 
The data regarding these exocrine nonductal tumours are summar-
ized in Table 2. In the 10 IPMT, 3 cases were found to have K-ras
mutation at codon 12 with no mutations in p16, p53 or DPC4.
No mutations in any of the 4 genes were found in PAC or SPT. All
the 5 PAC tested showed strong to intermediate cytoplasmic
immunostaining with anti-DPC4 antibodies (Fig. 5). Both invasive
and all noninvasive components of the tested IPMT labelled posit-
ively for DPC4, as was seen in the 4 tested cases of SPT. 
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The results of the mutational analysis in the 16 AVC are summar-
ized in Table 3. Mutations of K-ras and p53 were found in 47%
and 60% of cases, respectively. One case had a mutation of the
DPC4 gene (6%), while 4 cases (25%) had inactivation of p16,
all of which were due to de novo methylation (Fig. 3).
Immunohistochemical staining for DPC4 revealed that 6 cases
(38%) were negative, including one case showing focal positivity.
The remaining 10 cases were all diffusely positive. Allelic loss on
chromosomal arms 9p, 17p, and 18q was detected in 13%, 63%
and 50% of cases. Our genetic and immunohistochemical analysis
showed that nine of 16 AVC had alterations in at least 2 of the 4
genes analysed, and that all cases showing either p16 or DPC4
alteration always showed alteration of either K-ras or p53. 
Endocrine tumours 
The data on the endocrine tumours is shown in Table 4. One
nonfunctioning (NF) case had a mutation in K-ras and another NF
tumour had a mutated p53 gene (Beghelli et al, 1998). One insuli-
noma was found to harbour a p16 mutation affecting a splice junc-
tion (Fig. 2). 4 patients (10%) had the A148T polymorphism in the
p16 gene. No alterations were found in DPC4. All of the 36 cases
tested stained positively for DPC4 antigen. 
DISCUSSION 
The results of the present extensive molecular analysis of different
primary pancreatic tumour types may be summarized as follows:
a) a relatively high frequency of DNA sequence alterations of
K-ras, p53 and p16 was detected in our panel of PDC, which is a
result largely concordant with previous studies on primary or
xenografted PDC; b) the detection of sequence mutations of DPC4
in PDC is at variance with a previous report on primary PDC and
in agreement with the findings with xenografted PDC; c) alter-
ations in K-ras, p53, p16 and DPC4 were found in a proportion of
AVC and were virtually absent in PET, PAC, SPT or IPMT, the
latter only showing relatively frequent K-ras mutations; d) the
inactivation of DPC4 gene by additional mechanisms such as
homozygous deletion could be addressed indirectly by using
immunohistochemistry, which showed the absence of the protein
in about half of PDC and AVC and its expression in PAC, SPT,
IPMT or PET. The extreme rarity of p16 alterations and the lack of
DPC4 inactivation in PET are at variance with previous reports. 
Primary ductal cancers 
As expected, in our series of 34 primary PDC we found mutations
in K-ras and p53 at a frequency largely concordant with those
observed in previous studies on primary cancers (Almoguera
et al, 1988; Hruban et al, 1993; Lemoine et al, 1992; Pellegata et
al, 1994; Redston et al, 1994; Scarpa et al, 1993a, 1994a).
Alterations of the p16 gene were found in 13/34 (38%) cases,
including 8 mutations (23%) and 5 cases with promoter methyla-
tion (15%). The p16 mutational frequency of 23% in our cases is
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AATTGGT G TTG ATGA CC TT
AA TT GG T G TTAAT G A CC TT i
Figure 1 Example of PCR-SSCP analysis of DPC4. A, SSCP analysis.
Only the case showing aberrant band migration is indicated. The tumour
showing altered migration is a ductal cancer. B, sequence analysis of a band
not showing altered migration (top panel) and of the band displaying aberrant
migration. The sequence substitution is indicated by an arrow. The






G ATCCAGG TGG G TAG A GG
G ATCCAGG AGG G TAG A GG
Figure 2 Example of PCR-SSCP analysis of p16 in primary tumours. A,
SSCP analysis. Only the case showing aberrant band migration is indicated.
The tumour showing altered migration is an insulinoma (PET-F11). B,
sequence analysis of a band not showing altered migration (top panel) and
of the band displaying aberrant migration. The sequence substitution is




MUM U MU M U MU
PaTu-I AVC3 AVC1 AVC4 AVC61
Figure 3 Representative examples of methylation-specific PCR of the p16
gene. In panels A and B case numbers are as indicated. M, PCR with
primers specific for methylated DNA. U, PCR with primers specific for
unmethylated DNA. The numbers indicate the size of the DNA marker in
base pairs. The expected sizes of the PCR products are 150 bp for p16
unmethylated DNA and 151 bp for methylated sequences. Methylation-






















Figure 4 Representative examples of microsatellite analysis of
microdissected cancers. Case numbers are as indicated to the right of each
pair of electropherogram tracings. NF, nonfunctional PET, F, functional PET.
N, normal; T, tumour. All samples show allelic loss (indicated by arrows)
except for the case in D. In B, it can be noticed that a neoplastic cellularity of
100% has not been achieved. The microsatellites used are as follows. A, B:
D9S171. C, D: D17S938. E, F: D18S474in good agreement with the 17% mutational frequency found in an
earlier study on 30 primary PDC (Huang et al, 1996) and reason-
ably close to the 35% found in 40 xenografts (Rozenblum et al,
1997). The present study is the first to address the frequency of
p16 promoter methylation in primary PDC and the results are in
excellent agreement with the 15–18% observed in xenografted
PDC and cell-lines (Schutte et al, 1997; Ueki et al, 2000).
Mutations in DPC4 were found in 9% of cases, at variance with
the only other study using primary cancers where no mutations
were found in 45 PDC (Bartsch et al, 1999a) and in agreement
with the 13% mutations found in a total of 45 xenografts
(Rozenblum et al, 1997; Villaneueva et al, 1998). 
Homozygous deletions are frequent inactivating events of p16
and DPC4 that can be easily detected in xenografted cancers, cell
lines or short term cultures (Caldas et al, 1994; Hahn et al, 1996;
Huang et al, 1996; Villanueva et al, 1998; Jonson et al, 1999).
Microdissected primary cancers are well suited for microsatellite
analysis and enabled us to demonstrate unequivocal allelic losses
on 9p, 17p and 18q in PDC in a high proportion of cases. However,
it is particularly problematic to assay primary PDC for homozy-
gous deletion, as their detection would require a cancer cellularity
approaching 100%. This cannot be achieved in the large majority
of PDC (compare panels A and B of Figure 4) due to the high
admixture with nonneoplastic cells. 
Immunohistochemistry however could be used as an alternative
to reveal p16 and DPC4 inactivation due to homozygous deletion.
Unfortunately, the status of p16 could not be reliably assessed by
this method. In fact, we have used 3 different antibodies with
different antigen-retrieval methods and enhancing procedures, all
with unsatisfactory results. It is also worth mentioning that in the
report from Wilentz et al, no normal pancreatic cell or structure
was immunostained, only a number of cells in hyperplastic ductal
epithelia were positive and the authors themselves reported diffi-
culty in interpretation due to significant cytoplasmic background
staining (Wilentz et al, 1998). Similar problems with p16 immuno-
histochemistry using 4 different commercial antibodies has also
been recently reported (Geradts et al, 2000). However, immuno-
histochemical staining for DPC4 consistently found positive
staining in all normal pancreatic acinar, ductal and islet cells. Of
particularly interest, 47% of PDC showed negative staining for the
protein. DPC4 immunohistochemistry has been recently shown to
correlate with inactivation of the gene in more than 90% of cases
(Wilentz et al, 2000). This would provide additional evidence that
homozygous deletion is a major mechanism of DPC4 inactivation
in ductal cancers. 
Intraductal papillary mucinous tumours 
To date, K-ras mutations have been found in IPMT at varying
frequency, ranging from 30 to 70% (Sessa et al, 1994; Satoh et al,
1996; Kondo et al, 1997; Z’Graggen et al, 1997). p53 mutations
are rare and associated with the invasive component of the tumour
(Sessa et al, 1994). In 10 cryostat-enriched cases of IPMT, 7 of
which had an invasive cancer component, we found 3 K-ras
mutations and no alteration of p16, p53 or DPC4. It would seem
reasonable to consider IPMT a tumour entity with molecular
targets involved in its pathogenesis distinct from those of ductal
carcinoma. The low frequency of LOH found on chromosomal
arms 9p, 17p, and 18q further substantiates this supposition. As
expected from these studies, all cases also stained positively for
DPC4. 
Acinar cancers 
In PAC, mutations in K-ras are exceedingly rare (Hoorens et al,
1993; Terhune et al, 1994) and p53 mutations have not been found
in 3 cases previously reported (Pellegata et al, 1994). Our 6 PAC
showed no K-ras nor p16 mutations and frequent allelic losses on
chromosomal arms 17p and 18q. However, our mutational analysis
showed that the targets of these chromosomal losses are not p53
nor  DPC4, the latter result being additionally substantiated by
immunohistochemistry. 
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Normal PAC5
PDC18 PDC9
Figure 5 Representative examples of
immunohistochemistry with anti-DPC4
antibodies. Acinar and ductal cells of normal
pancreas show positive staining, as do the
shown cases of acinar cancer (PAC5) and
pancreatic ductal carcinoma (PDC9).
Pancreatic ductal cancer PDC18 is
immunonegative Solid pseudopapillary tumours 
Neither ras gene family mutations nor alterations in p53 have been
found in SPT (Lee et al, 1997; Bartsch et al, 1998). Our 5
cases confirmed this data. We found no alterations in either p16
or DPC4 and no allelic losses on either 9p, 17p or 18q.
Immunohistochemistry showed positive staining for DPC4, as
expected. Thus, the molecular events leading to this peculiar entity
remain elusive. 
Ampulla of Vater cancers 
Our series of 16 AVC was composed of small neoplasms (<3 cm)
of unequivocal ampullary origin, and cases showing microsatellite
instability were excluded (Achille et al, 1997). Alterations were
found in all 4 genes, with p53 mutations being the most frequent
event (60%), accompanied in the majority of cases by the loss of
the second allele. K-ras mutations were detected in 47% of cases.
One case had a mutation in the DPC4 gene (6%) accompanied by
the loss of the second allele, while 4 cases had inactivation of p16
(25%) by promoter methylation. The most frequent allelic losses
were on chromosomal arm 17p (63%), which has recently been
found to be an independent prognostic factor among ampullary
cancers at the same stage (Scarpa et al, 2000). Allelic loss on
chromosomal arm 18q was a relatively frequent event (50%), while
9p LOH was infrequent (13%). Interestingly, 38% of cases showed
negative staining for DPC4. This would imply that homozygous
deletion of the DPC4 gene is a frequent inactivating event in these
tumours as for ductal cancers and reinforces the hypothesis that
these two tumour types share common molecular pathways related
to tumourigenesis and, possibly, progression of malignancy. 
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Table 1 Molecular alterations of K-ras, p53, p16 and DPC4 in primary pancreatic ductal cancers* 
K-ras p53 p16 DPC4
Predicted Predicted  Allelic  Predicted  Allelic Predicted Allelic
Alteration effect Alteration effect Loss § Alteration effect Loss § Alteration effect Loss § IHC** 
PDC3 c35G>A G12D c471–476del5 bp frameshift LOH none Nl none Nl + 
PDC4 c35G>A G12D none ret c269insT frameshift LOH none LOH +
PDC5 none c746G>T R249M LOH none ret none ret + 
PDC6 none c796G>T G266X Nl none ret none LOH + 
PDC9 none none ret methylated absent ret none ret + 
PDC10 c35G>T G12V c718delA frameshift LOH none ret none LOH + 
PDC11 c34G>A G12S none LOH c128insA Y44X LOH c1320del
58bp> TG frameshift LOH -
PDC13 c35G>T G12V none LOH none ret c1798C> T polymorphism LOH -
PDC14 c35G>T G12V c657delC frameshift LOH none LOH none LOH + 
PDC15 c35G>A G12D none LOH none LOH none ret + 
PDC16 c35G>T G12V c747G>T R249S LOH c141C>A P48T LOH none LOH + 
PDC17 c35G>T G12V none ret methylated absent ret none LOH not done 
PDC18 c35G>T G12V c817C>T R273C LOH none LOH c1798C>T polymorphism Nl -
PDC19 c35G>T G12V c395A>G K132R LOH none LOH none LOH -
PDC20 c35G>A G12D c454–455delCC frameshift Nl none LOH none LOH -
PDC21 c35G>A G12D c745A>G R249G ret none LOH none ret not done 
PDC22 c35G>T G12V none ret methylated absent LOH none LOH not done 
PDC23 c35G>A G12D none LOH none ret c1086T>C polymorphism ret +
PDC24 none none ret c442G>A polymorphism ret none ret -
PDC25 c35G>T G12V c729ins7bp frameshift LOH none ret none ret -
PDC26 c35G>T G12V none LOH methylated absent LOH none ret not done 
PDC27 c35G>A G12D none LOH none LOH c1569C>G CS23W LOH - 
PDC28 c35G>A G12D none Nl none ret none ret -
PDC29 c35G>A G12D c530C>G P177R LOH c171–177del in-frame del LOH none LOH - 
PDC30 c35G>A G12D none LOH c230–231delCT frameshift LOH none LOH + 
PDC31 none none LOH c328G>A W110X LOH none LOH + 
PDC32 none none LOH none LOH none LOH + 
PDC33 c35G>T G12V c742G>A R248Q LOH c284T>G L94R LOH c1477G>A D493N LOH -
PDC34 c35G>T G12V c818G>A R273H LOH none LOH none Nl +/-
PDC35 c34G>C G12R c818G>T R273L LOH methylated absent LOH none LOH + 
PDC36 c34G>C G12R c844C>T R282W LOH c165ins10 bp frameshift LOH none ret + 
PDC37 c35G>A G12D none LOH none LOH none LOH -
PDC38 c35G>A G12D c641A>G H214R LOH c442G>A polymorphism ret none ret -
PDC39 c35G>T G12V c524G>A R175H ret none LOH none LOH + 
28/34 18/34 24/31 13/34 22/33 3/34 20/31 14/30 
82% 53% 77% 38% 67% 9% 65% 47% 
*Mutations of K-ras and p53 and allelic loss data on selected tumours are from Scarpa et al, 1993 and Achile et al, 1996. See Materials and methods for details. 
**IHC immunohistochemistry: +, positive staining neoplastic cells: -, negative staining neoplastic cells; +/- focal positive staining. § LOH, loss of heterozygosity:
ret, retention of alleles; Nl, noninformative. Mutational spectra of pancreatic tumours 259
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Table 2 Molecular alterations of K-ras, p53, p16 and DPC4 in primary pancreatic exocrine nonductal tumours* 
K-ras p53 p16 DPC4
Predicted Predicted Allelic Predicted Allelic Predicted Allelic
Alteration product Alteration product Loss § Alteration product Loss § Alteration product Loss § IHC*** 
IPMT** 
IPMT1** none found none found ret none found ret none found ret + 
IPMT2** none found none found ret none found Nl none found ret + 
IPMT3** none found none found ret none found ret none found ret not done 
IPMT4* c35G>A G12D none found ret none found ret none found ret not done 
IPMT5*** none found none found ret none found ret none found ret + 
IPMT6* none found none found ret none found ret none found ret + 
IPMT7** none found none found ret none found ret none found ret + 
IPMT8** none found none found LOH none found ret none found ret not done 
IPMT9* c35G>T G12V none found LOH none found ret none found LOH + 
IPMT10** c35G>A G12D none found ret none found ret none found ret -
3/10 0/10 2/10 0/10 0/9 0/10 1/10 0/7 
30% 20% 10%
Acinar carcinoma 
PAC1 none found none found ret none found ret none found LOH not done 
PAC2 none found none found LOH none found LOH none found LOH + 
PAC3 none found none found Nl none found Nl none found ret + 
PAC4 none found none found LOH none found ret none found ret + 
PAC5 none found none found not done none found not done none found not done + 
PAC6 none found none found ret none found ret none found ret -
0/6 0/6 2/4 0/6 1/4 0/6 2/5 0/5 
50% 25% 40%
Solid-pseudopapillary tumour 
SPT1 none found none found ret none found ret none found ret + 
SPT2 none found none found ret none found ret none found ret + 
SPT3 none found none found ret none found ret none found ret + 
SPT4 none found none found not done not done not done not done not done not done 
SPT5 none found none found ret none found ret none found ret + 
0/5 0/5 0/4 0/4 0/4 0/4 0/4 0/4 
*Mutations of K-ras and p53 on selected IPMT are from Sessa et al, 1994. See Materials and methods for details. **IPMT, Intraductal papillary-mucinous
tumour: *, borderline; **, muconodular cancer component: *** ductal cancer component. ***IHC, immunohistochemistry; +, positive staining neoplastic cells; -,
negative staining neoplastic cells; +/- focal positive staining. § LOH, loss of heterozygosity; ret, retention of alleles; Nl, noninformative. 
Table 3 Molecular alterations of K-ras, p53, p16 and DPC4 in ampulla of Vater cancers*
K-ras p53 p16 DPC4 
Predicted Predicted Allelic Predicted  Allelic Predicted  Allelic
Alteration effect Alteration effect Loss § Alteration effect Loss § Alteration effect Loss § IHC** 
AVC1 none c733G>A G245D LOH none ret none LOH + 
AVC3 none c659A>G Y22OC LOH methylated absent ret none LOH -
AVC4 c35G>A G12D none ret none ret none ret + 
AVC5 none c733G>C G245R LOH methylated absent ret none ret + 
AVC6 none c535C>T H179Y LOH none ret none ret -
AVC7 none none ret none ret none ret + 
AVC8 none c657delC frameshift LOH none LOH none LOH + 
AVC9 c35G>C G12A c517G>A V173M ret none ret none ret + 
AVC12 none c845G>T R282L LOH none ret none LOH -
AVC13 c35G>A G12D c637C>T R213X LOH c442G>A polymorphism ret none LOH -
AVC14 c35G>A G12D none LOH methylated absent ret none LOH -
AVC15 none none LOH c442G>A polymorphism ret none ret + 
AVC17 c35G>A G12D none ret none LOH none ret + 
AVC19 c35G>A G12D c524G>A R175H ret none ret c1050-1065del in-frame del LOH +/-
AVC60 not done not done ret none ret none ret + 
AVC61 c35G>C G12A none LOH methylated absent ret none LOH + 
7/15 9/15 10/16 4/16 2/16 1/16 8/16 6/16 
47% 60% 63% 25% 13% 6% 50% 38% 
*Mutations of K-ras and p53 and some allelic loss data on tumours AVC1-60 are from Scarpa et al, 2000. See Materials and methods for details. **IHC,
immunohistochemistry; +, positive staining neoplastic cells; - , negative staining neoplastic cells; +/- focal positive staining. § LOH, loss of heterozygosity; ret,
retention of alleles; Nl, noninformative. Endocrine tumours 
Our data confirm the extreme rarity of mutations in K-ras and p53
in these tumours (Beghelli et al, 1998; Ebert et al, 1998; Lam and
L.O, 1998). The rarity of p53 mutations accompanied by LOH on
chromosome 17p in 50% of nonfunctional cases, but in none of the
functional PET, supports a previous suggestion indicating the pres-
ence of a tumour suppressor gene other than p53 on chromosomal
arm 17p involved in nonfunctional PET tumourigenesis (Beghelli
et al, 1998). The virtual absence of p16 and DPC4 alterations in our
41 cases was somewhat unexpected given the recent reports of high
frequency of inactivation of these genes in PET (Muscarella et al,
1998; Bartsch et al, 1999b). In our 41 PETs, only one insulinoma
showed a p16 alteration and no case showed alteration in the DPC4
gene, in spite of the finding of a moderately frequent LOH on chro-
mosomal arms 9p and 18q, found in 39% and 30% of nonfunctional
and 13% and 40% of functional tumours, respectively. 
In a study of 12 PETs, the p16 gene has been reported to be
altered in 92% of cases (7/8 gastrinomas and 4/4 nonfunctional)
by either methylation (58%) or homozygous deletion (42%)
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Table 4 Molecular alterations of K-ras, p53, p16 and DPC4 in pancreatic endocrine tumours* 
K-ras p53 p16 DPC4
Predicted Predicted  Allelic  Predicted  Allelic Predicted  Allelic
Alteration product Alteration product Loss § Alteration product Loss § Alteration product Loss § IHC** 
NF1 none none ret none ret none LOH + 
NF2 none none LOH none ret none LOH + 
NF3 none none ret none ret none ret + 
NF4 none none LOH none ret none ret + 
NF5 none none ret none ret none ret + 
NF6* none none LOH none ret none ret + 
NF7* none none LOH c442G>A polymorphism ret none LOH + 
NF8** none none LOH none ret none ret + 
NF9** none c709delG frameshift LOH none LOH none ret + 
NF10* c35G>A G12D none LOH none LOH none LOH + 
NF17* none none ret none LOH none ret + 
NF18* none none ret c442G>A polymorphism LOH none ret not done 
NF19 none none LOH none Nl none ret + 
NF20* none none ret none LOH none ret + 
NF21* none none LOH none LOH none LOH not done 
NF22** none none ret none ret none LOH + 
NF23 none none ret none ret none LOH + 
NF24* none none ret none ret none ret + 
NF25 none none ret none LOH none LOH + 
NF26* none none LOH none Nl none ret + 
NF27 none none LOH none LOH none ret + 
NF28 none none LOH none ret none ret + 
NF29** none none ret none LOH none ret + 
NF30 none none ret none ret none ret not done 
NF31 none none LOH none ret none ret + 
NF32 none none LOH none LOH none ret + 
NF33 none none LOH none ret none LOH + 
NF34 none none ret none LOH none ret + 
NF35 none none ret none ret none ret + 
NF36 none none ret c442G>A polymorphism ret none ret + 
1/30 1/30 15/30 0/30 11/28 0/30 9/30 0/27 
3% 3% 50% 39% 30%
F1 none none ret none Nl none LOH + 
F2 none none ret none LOH none ret + 
F3 none none ret none ret none LOH + 
F4 none none ret none ret none ret + 
F5 none none ret none ret none ret + 
F6 none none ret none ret none LOH + 
F11 none none ret g152T>A splicing error ret none ret not done 
F12 none none ret none ret none ret + 
F13 none none ret c442G>A polymorphism Nl none ret not done 
F14^ none none ret none ret none LOH + 
F15^^ not done not done not done none not done none not done + 
0/10 0/10 0/10 1/11 1/8 0/11 4/10 0/9 
9% 13% 40%
*NF, nonfunctional; F, functional; ^ViPoma; ^^Gastrinoma. Mutations of K-ras and p53 and some allelic loss data on cases NF1–10 and F1-7 are from Beghelli
et al, 1998. See materials and methods for details. **IHC, immunohistochemistry; +, positive staining neoplastic cells; - , negative staining neoplastic cells;
+/- focal positive staining. Malignant case (see Methods). Malignant case with liver metastasis. § LOH, loss of heterozygosity; ret, retention of alleles;
Nl, noninformative. (Muscarella et al, 1998). In our series, only one insulinoma had a
mutation in p16 and none of the 41 PETs showed p16 methylation.
The sensitivity of our methylation-specific PCR rules out the
possibilities that tumour heterogeneity or neoplastic cellularity
might have biased this result. It is possible that p16 inactivation by
promoter methylation might be restricted to functional gastri-
nomas, as all the reported PETs showing p16 methylation were of
this subtype (Muscarella et al, 1998). Moreover, neoplastic cellu-
larity is not as problematic in PET with respect to PDC and virtu-
ally all cases can be enriched to nearly 100%. We observed no
homozygous deletions of the p16 gene under identical, standard
amplification conditions previously used (Muscarella et al, 1998).
Although it cannot be excluded that a small proportion of PETs
have homozygous deletion of p16, it would appear to be a rare
event. Finally, although the A148T polymorphism in the p16 gene
in was found in 10% of patients, which is well above the expected
frequency (1.8%) (Aitken et al, 1999), this sequence variant has
been reported to be functionally silent (Reymond and Brent 1995)
and was not of statistically significant risk in families with
melanoma (Aitken et al, 1999). 
A recent study reported DPC4 alterations in 5 of 9 malignant
nonfunctional PET and in none of 16 functional PET, where it was
suggested that alteration of this gene was correlated with malig-
nancy (Bartsch et al, 1999b). Only one of these 5 alterations
resulted from homozygous deletion, with the remaining 4 being
mutations. We observed neither mutations nor homozygous dele-
tions in the DPC4 gene in our series of 11 functional and 30
nonfunctional enriched tumours. The latter included 18 malignant
cases, 10 of which had liver metastases. Thus, our data suggest that
the DPC4 is not likely to play a central role in neuroendocrine
tumourigenesis and the previously reported data may be biased by
serendipity due to the small number of cases studied (Bartsch et al,
1999b). The conclusions reached from our molecular analysis of
the DPC4 gene in PET is further strengthened by results from
immunohistochemistry in which all cases tested stained positively.
Thus, it would appear unlikely that homozygous deletion of the
DPC4 gene is a frequent event in PET. 
CONCLUSIONS 
By the molecular analysis of 112 pancreatic tumours of different
types, it can be inferred that only carcinomas arising from the
epithelium of pancreatic ducts and their terminal excretory struc-
ture (ampulla of Vater) have common molecular features. The
genetic pathways implicated in ductal cancer are not involved in
the pathogenesis of exocrine nonductal or endocrine tumours.
These neoplasms must therefore have distinct molecular pathways
involved in tumourigenesis. This likelihood seems highly plaus-
ible when considered together with the fact that each tumour type
has distinct pathological and clinical features, including dramatic
differences in patient survival. 
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